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CHANGES IN BLOOD LIPID LEVELS INDUCED BY DIFFERENT DIETARY
FAT TYPES ARE NOT INFLUENCED BY PRE-SUPPLEMENTATION WITH
FISH OIL
C.B. Dias 1, L.G. Wood 2, M.L. Garg 2. 1Nutraceuticals Research group, School
of Biomedical Sciences and Pharmacy, University of Newcastle, NSW,
Australia; 2 School of Biomedical Sciences & Pharmacy, University of
Newcastle, NSW, Australia
E-mail address: cintia.dias@uon.edu.au (C.B. Dias)
Background/Aims: Although, the health beneﬁts of long chain n-3PUFA
arewell known, the effects of n-3PUFA status on blood lipid modulation by
background dietary fats is not well understood. Therefore, this study
aimed to determine the effects of diets high in either saturated fatty acids
(SFA) or n-6PUFA following pre-supplementation with n-3PUFA.
Methods: This was a randomised, controlled, parallel, dietary intervention
trial involving 22 healthy adults aged 18 to 65 years. Participants
consumed 2.4 g n-3PUFA daily for 4 weeks and then were randomized to
one of 2 diets, enriched either with SFA or n-6PUFA combined with 2.4 g n-
3PUFA daily for at least 10 days. Blood samples and anthropometric
measurements were collected after an overnight fast, at baseline, after 4
weeks and post-intervention. Blood samples were assessed for lipid [total,
low density lipoprotein (LDL) and high density lipoprotein (HDL) choles-
terol and triglyceride] levels.
Results: Pre-supplementation with n-3PUFA decreased plasma tri-
glycerides (p¼ 0.006) and increased HDL cholesterol (p ¼ 0.032) and body
mass index (BMI; p < 0.001) signiﬁcantly. After the SFA and n-6PUFA diets
no further changewas observed in plasma triglycerides, HDL cholesterol or
BMI. The SFA diet caused an increase in total and LDL cholesterol (p¼ 0.008
and p ¼ 0.013, respectively), while the n-6PUFA diet caused a decrease in
total and LDL cholesterol (p ¼ 0.003, both).
Conclusions: Pre-supplementation with n-3PUFA does not inﬂuence
changes in blood lipid levels induced by type of background dietary fat.
Funding source(s): Hunter Medical Research Institute (HMRI) and Coor-
denaç~ao Nacional de Desenvolvimento Cientíﬁco e Tecnologico (CNPq,
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IS COGNITIVE IMPAIRMENT IN POSTMENOPAUSAL WOMEN
ATTRIBUTABLE TO POOR CEREBRAL PERFUSION? BASELINE RESULTS
OF THE RESFEM STUDY
H. Evans, R. Wong, P. Howe. Clinical Nutrition Research Centre, University of
Newcastle, NSW, Australia
E-mail address: c3164368@uon.edu.au (H. Evans)
Background/Aims: Postmenopausal women suffer disproportionately
from dementia, which we hypothesise may be partly attributable to loss of
cerebrovascular beneﬁts of oestrogen. We are currently testing whether a
14 week supple-mentationwith resveratrol (a phytoestrogen) can improve
cerebral perfusion and cognition in postmenopausal women. Herein, we
present baseline evaluation of these parameters.
Methods: Eighty postmenopausal women aged 45-85 years underwent
cognitive testing; domains of executive function, semantic, verbal and
visuospatial working memory were scored individually and as a compos-
ite. Transcranial Doppler ultrasound was used to record basal blood ﬂow
velocity in the middle cerebral artery (MCA) and a pulsatility index (PI),
reﬂecting stiffness of the vessel, was calculated. Cerebrovascular respon-
siveness (CVR) to the cognitive testing, which reﬂects the ability of a brain
region to vasodilate in response to demands, was expressed as the per-
centage change in mean blood ﬂow velocity from the basal level recorded
for 30 sec before tests to the peak velocity attained during testing
Results: Using Pearson’s correlation, we found that the composite cogni-
tive score correlated with PI (r ¼ -0.291, p ¼ 0.017), the basal mean blood
ﬂow velocity (r¼ 0.34, p¼ 0.005) and CVR to the test battery (r¼ 0.301, p¼
0.017) in the MCA.
Conclusions: Our baseline assessment of post-menopausal women shows
that cognitive performance is linked to cerebrovascular function, at rest
and during activation. Therefore, optimising cerebral perfusion may helpto attenuate cognitive decline in this at-risk population.
Funding source(s): Hunter Medical Research Institute 3D Healing Project
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Background/Aims: To determine the feasibility of undertaking a dietary
supplementation trial to evaluate ﬁsh oil as an adjunct therapy for chronic
obstructive pulmonary disease (COPD).
Methods: A double-blind, randomised controlled parallel trial was un-
dertaken to compare the effects of ﬁsh oil versus corn oil placebo (six 1 g
capsules/day orally for 16 weeks) on respiratory function, dyspnoea,
functional exercise capacity and well-being. The following a priori feasi-
bility criteria were evaluated: ability to recruit 40 participants within 52
weeks, 80% participant retention rate, and a moderate sized effect in at
least three outcome measures.
Results: Of 267 potential participants, 101 declined to participate and 91
were unable to be contacted. Of those willing to participate 62 were
excluded at the telephone screening, the most common reasons being
participants were taking ﬁsh oil (n¼ 20), did not have COPD (n¼ 10), were
participating in another study (n ¼ 7) or, at visit 1, had a signiﬁcant
bronchodilator response (n ¼ 13). Only13 were enrolled (7 in the initial 52
weeks), 9 of whom completed the 16 week intervention. Participants
withdrew from the study due to illness (n ¼ 2), injury unrelated to the
study (n ¼ 1) or an adverse event (n ¼ 1). There was one moderate sized
change (impulse oscillometry, effect size -0.56).
Conclusions: This preliminary trial did not meet the pre-determined key
feasibility criteria, which raises doubts as to whether we can ascertain the
efﬁcacy of omega-3 supplementation in COPD using this approach.
Funding source(s): None.
DOES CAFFEINE CONSUMPTION DURING 50 H OF SLEEP DEPRIVATION
ALTER GLUCOSE METABOLISM, HUNGER AND SATIETY RATINGS?
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Background/Aims: Sustained operations are common in military and
emergency services. In these operations it is not always possible to obtain
sleep, resulting in sleep deprivation. Caffeine is a widely used fatigue
countermeasure. However, the impact of caffeine on glucose metabolism,
hunger, and satiety during sleep deprivation is largely unknown.
Methods: In this double-blinded laboratory based study, participants were
assigned to either a caffeine (n ¼ 12, 4F, 22.5 ± 3.3 y, 21.7 ± 1.5 kg/m2) or
placebo condition (n ¼ 12, 5F, 22.5 ± 2.5 y, 22.3 ± 2.1 kg/m2). The protocol
included one baseline sleep (22:00he08:00h), 50h sleep deprivation and a
daytime recovery sleep (10:00he19:00h). Caffeine (200 mg) or placebo
gum was chewed for 5min at 01:00h, 03:00h, 05:00h and 07:00h during
each night of sleep deprivation. Meal timing and composition were
controlled throughout the study; breakfast composition z1611 kJ; 16%
protein,z73% carbohydrate and 3% total fat. Interstitial continual glucose
monitors captured 2h post-breakfast levels, at 5min intervals. Hunger/
satiety scales were administered at 10:00h after 26h of sleep deprivation.
Results: Relative to baseline (6.1 ± 0.5 mmol/L) sleep deprivation led to
increased mean glucose 2h post breakfast at 24h sleep deprived (6.5 ± 0.5
mmol/L, p < 0.001) and 48h sleep deprived (7.1 ± 0.5 mmol/L, p < 0.001).
There was no difference between placebo and caffeine conditions (p ¼
